Update on first-line treatment of advanced ovarian carcinoma

References

• FerlayJShinHRBrayFCancer incidence and mortality worldwideIARC Cancer Base No 10Lyon, FranceInternational Agency for Research on Cancer2010 Available from: http://globocan.iarc.frAccessed December 14, 2012
   Google Scholar
• JemalASiegelRWardEHaoYXuJThunMJCancer statistics, 2009CA Cancer J Clin200959422524919474385
   PubMed Web of Science ®Google Scholar
• GoffBAMandelLSDrescherCWDevelopment of an ovarian cancer symptom index: possibilities for earlier detectionCancer2007109222122717154394
   PubMed Web of Science ®Google Scholar
• Hippisley-CoxJCouplandCIdentifying women with suspected ovarian cancer in primary care: derivation and validation of algorithmBMJ2011344d800922217630
   PubMed Web of Science ®Google Scholar
• BuysSSPartridgeEBlackAEffect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trialJAMA2011305222295230321642681
   PubMed Web of Science ®Google Scholar
• MenonUKalsiJJacobsIThe UKCTOCS experience – reasons for hope?Int J Gynecol Cancer201222 Suppl 1S18S2022543913
   PubMed Web of Science ®Google Scholar
• McGuireW PHoskinsWJBradyMFCyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancerN Engl J Med19963341167494563
   PubMed Web of Science ®Google Scholar
• PiccartMJBertelsenKJamesKRandomized Intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year resultsJ Natl Cancer Inst200092969970810793106
   PubMed Web of Science ®Google Scholar
• du BoisANeijtJ PThigpenJTFirst line chemotherapy with carbo-platin plus paclitaxel in advanced ovarian cancer – a new standard of care?Ann Oncol199910 Suppl 1354110219451
   PubMed Web of Science ®Google Scholar
• VaseyPAJaysonGCGordonAPhase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinomaJ Natl Cancer Inst200496221682169115547181
   PubMed Web of Science ®Google Scholar
• International Collaborative Ovarian Neoplasm GroupPaclitaxel plus carboplatin versus standard chemotherapy with either singleagent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trialLancet2002360933250551512241653
   PubMed Web of Science ®Google Scholar
• MuggiaFMBralyPSBradyMFPhase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group studyJ Clin Oncol200018110611510623700
   PubMed Web of Science ®Google Scholar
• du BoisAQuinnMThigpenT2004consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)Ann Oncol200516Suppl 8viii7viii1216239238
   PubMedGoogle Scholar
• BookmanMABradyMFMcGuireW PEvaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III trial of the Gynecologic Cancer IntergroupJ Clin Oncol20092791419142519224846
   PubMed Web of Science ®Google Scholar
• van der BurgMEvan LentMBuyseMThe effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of CancerN Engl J Med1995332106296347845426
   PubMed Web of Science ®Google Scholar
• VergoteIAmantFLeunenKNeoadjuvant chemotherapy in advanced ovarian cancer: what kind of evidence is needed to convince US gynaecological oncologists?Gynecol Oncol201011911220833283
   PubMed Web of Science ®Google Scholar
• OndaTMatsumotoKShibataTPhase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602Jpn J Clin Oncol2008381747718258715
   PubMed Web of Science ®Google Scholar
• VergoteITropeCGAmantFEhlenTReedNSCasadoANeoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancerJ Clin Oncol201129314076407821931032
   PubMed Web of Science ®Google Scholar
• Rauh-HainJARodriguezNGrowdonWBPrimary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancerAnn Surg Oncol201219395996521994038
   PubMed Web of Science ®Google Scholar
• MarkmanMBundyBNAlbertsDSPhase III trial of standarddose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology GroupJ Clin Oncol20011941001100711181662
   PubMed Web of Science ®Google Scholar
• ArmstrongDKBundyBWenzelLIntraperitoneal cisplatin and paclitaxel in ovarian cancerN Engl J Med20063541344316394300
   PubMed Web of Science ®Google Scholar
• SeidmanADBerryDCirrincioneCRandomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: fnal results of Cancer and Leukemia Group B protocol 9840J Clin Oncol200826101642164918375893
   PubMed Web of Science ®Google Scholar
• SparanoJAWangMMartinoSWeekly paclitaxel in the adjuvant treatment of breast cancerN Engl J Med2008358161663167118420499
   PubMed Web of Science ®Google Scholar
• KatsumataNYasudaMTakahashiFDose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trialLancet200937496981331133819767092
   PubMed Web of Science ®Google Scholar
• KatsumataNYasudaMIsonishiSLong-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trialJ Clin Oncol201230Suppl Abstr 5003
   Google Scholar
• BolisGFavalliGDaneseSWeekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytore-ductive surgery for advanced ovarian cancerJ Clin Oncol1997155193819449164205
   PubMed Web of Science ®Google Scholar
• CocconiGBellaMLotticiRMature results of a prospective randomized trial comparing a three-weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinomaAm J Clin Oncol199922655956710597739
   PubMed Web of Science ®Google Scholar
• FruscioRGarbiAParmaGRandomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancerJ Natl Cancer Inst2011103434735121217084
   PubMedGoogle Scholar
• KrivakTCDarcyKMTianCSingle nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group studyGynecol Oncol2011122112112621496891
   PubMed Web of Science ®Google Scholar
• O’DonnellPHGamazonEZhangWPopulation differences in platinum toxicity as a means to identify novel genetic susceptibility variantsPharmacogenet Genomics201020532733720393316
   PubMed Web of Science ®Google Scholar
• HuangSRobinsonJBDeguzmanABucanaCDFidlerIJBlockade of nuclear factor-kappaB signaling inhibits angiogenesis and tum-origenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8Cancer Res200060195334533911034066
   PubMed Web of Science ®Google Scholar
• BurgerRASillM WMonkBJGreerBESoroskyJIPhase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group StudyJ Clin Oncol200725335165517118024863
   PubMed Web of Science ®Google Scholar
• CannistraSAMatulonisUAPensonRTPhase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancerJ Clin Oncol200725335180518618024865
   PubMed Web of Science ®Google Scholar
• PerrenTJSwartAMPfstererJA phase 3 trial of bevacizumab in ovarian cancerN Engl J Med2011365262484249622204725
   PubMed Web of Science ®Google Scholar
• BurgerRABradyM FBookmanMAIncorporation of bevacizumab in the primary treatment of ovarian cancerN Engl J Med2011365262473248322204724
   PubMed Web of Science ®Google Scholar
• StuartGCKitchenerHBaconM2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus ConferenceInt J Gynecol Cancer201121475075521543936
   PubMed Web of Science ®Google Scholar
• HanESMonkBJWhat is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?Gynecol Oncol200710513617383545
   PubMed Web of Science ®Google Scholar
• AghajanianCBlankS VGoffBAOCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancerJ Clin Oncol201230172039204522529265
   PubMed Web of Science ®Google Scholar
• FriedlanderMHancockKCRischinDA Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancerGynecol Oncol20101191323720584542
   PubMed Web of Science ®Google Scholar
• LedermannJAHackshawAKayeSRandomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancerJ Clin Oncol201129283798380421859991
   PubMed Web of Science ®Google Scholar
• KarlanBYOzaAMRichardsonGERandomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancerJ Clin Oncol201230436237122184370
   PubMed Web of Science ®Google Scholar
• HessVA’HernRNasiriNMucinous epithelial ovarian cancer: a separate entity requiring specific treatmentJ Clin Oncol20042261040104415020606
   PubMed Web of Science ®Google Scholar
• LeeYYKimTJKimMJPrognosis of ovarian clear cell carcinoma compared to other histological subtypes: a meta-analysisGynecol Oncol2011122354154721640372
   PubMed Web of Science ®Google Scholar
• MackayHJBradyMFOzaAMPrognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancerInt J Gynecol Cancer201020694595220683400
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research NetworkIntegrated genomic analyses of ovarian carcinomaNature2011474735360961521720365
   PubMed Web of Science ®Google Scholar
• GourleyCMichieCORoxburghPIncreased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotypeJ Clin Oncol201028152505251120406939
   PubMed Web of Science ®Google Scholar
• TanDSRothermundtCThomasK“BRCAness” syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutationsJ Clin Oncol200826345530553618955455
   PubMed Web of Science ®Google Scholar
• BoltonKLChenevix-TrenchGGohCAssociation between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancerJAMA2012307438239022274685
   PubMed Web of Science ®Google Scholar
• BanerjeeSKayeSBAshworthAMaking the best of PARP inhibitors in ovarian cancerNat Rev Clin Oncol20107950851920700108
   PubMed Web of Science ®Google Scholar
• LedermannJHarterPGourleyCOlaparib maintenance therapy in platinum-sensitive relapsed ovarian cancerN Engl J Med2012366151382139222452356
   PubMed Web of Science ®Google Scholar